United Citizens Foundation

Vaxxinity and the University of Central Florida launch an effort to advance space medicine research and prevent bone and muscle density loss during long space flights. Vaxxinity, an immunotherapeutic vaccine developer, is boldly going into partnership with the University of Central Florida to advance space medicine research. The effort, which is being funded by a grant from the State of Florida, will focus on developing Vaxxinity’s immunotherapies to prevent and mitigate muscle and bone wasting, which are health challenges related to long-term spaceflight, the company said in a Jan. 18 release. The research will include studies of the company’s active immunotherapies on undisclosed proteins implicated with bone and muscle growth through in vitro and in vivo experiments, as well as animal models established by the university. As part of the collaboration, Vaxxinity will provide materials including drug candidates derived from its platform to support the collaborative research. “If humanity is to become a spacefaring species, solving fundamental problems related to space travel and living are table-stakes,” Lou Reese, executive chairman of Vaxxinity, said in the release. “Vaxxinity is all-in on developing and commercializing these solutions, and working with the State of Florida and UCF, collectively, we strive to promote both healthy aging and ensure humanity can become multi-planetary, brave low gravity exposure, and be of the stars.” Vaxxinity, which is based in Cape Canaveral in Florida, raised $78 million in its 2021 IPO just months after coming together in a deal between COVAXX and United Neuroscience. At the time the company launched it touted its synthetic peptide vaccine platform as having the potential to enable a new class of medicines.

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases. “If humanity is to become a spacefaring species, solving fundamental problems related to space travel and living are table-stakes. Vaxxinity is all-in on developing and commercializing these solutions, and working with the State of Florida and UCF, collectively, we strive to promote both healthy aging and ensure humanity can become multi-planetary, brave low gravity exposure, and be of the stars,” says Lou Reese, Executive Chairman of Vaxxinity. “The support for this research from the State of Florida exemplifies a commitment to pioneering solutions in the fields of space travel, as well as longevity and age-related diseases.” Research will include studies to assess the effects of Vaxxinity’s active immunotherapies on undisclosed proteins implicated with bone and muscle growth through in vitro and in vivo experiments, and animal models established by UCF. Vaxxinity’s platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets. The company will provide materials including candidates derived from its platform to support the collaborative research at UCF. “UCF was born as a university to support the space program, and the College of Medicine is continuing that mission, working to bring back to Earth the secrets that space medicine research can reveal,” said Dr. Deborah German, vice president for health affairs and dean of UCF’s College of Medicine. “We look forward to collaborating with Vaxxinity on this research and applying their unique technology to benefit the aging population on our planet and future space travelers.” Reese concluded, “The research we are doing targeted towards space-based physical challenges is directly translatable to issues faced by humanity here on Earth. We know what we do for tomorrow will yield results for today.” About Vaxxinity Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. For more information about Vaxxinity, Inc., visit http://www.vaxxinity.com and follow us on social media @vaxxinity. About UCF The University of Central Florida is a public metropolitan research university in Orlando that unleashes the potential of people and ideas to positively change the world. UCF’s world-class faculty bring academic and industry expertise and innovative research to the classroom, educating and inspiring the talent that fuels America’s economy and solves society's greatest challenges. Founded in 1963 to support the U.S. space program, UCF today enrolls more than 68,000 students, offers 240 degree programs and is shaping the future of engineering and computer science, optics, modeling and simulation, healthcare, hospitality, digital media and many other industries. U.S. News & World Report ranks UCF as the No. 14 most innovative university in the country. Washington Monthly ranks UCF as the No. 36 best university in the nation and among the top 20 schools in the nation for social mobility, recognizing UCF’s efforts to empower student success through innovative efforts that engage and support student learning, service and research. Forward-looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "may," "continue," "advancing," "will" and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, initiation, duration, enrollment, results or timing for availability of results of, development of any of Vaxxinity’s product candidates or programs; the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial; the potential future regulatory authorization or approval and commercialization of Vaxxinity’s product candidates; the potential benefits or competitive position of any Vaxxinity product candidate or program or the commercial opportunity in any target indication; and Vaxxinity’s plans, expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Vaxxinity’s management about the development of a new class of immunotherapeutic vaccines and the innovation and efficacy of Vaxxinity’s product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including, but not limited to: whether UB-311, UB-312, UB-313, VXX-401, UB-612 or any other current or future product candidate of Vaxxinity will be approved or authorized by any regulatory agency for the indications that Vaxxinity targets; any potential negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of Vaxxinity’s business; Vaxxinity’s product candidates may not be successful or clinical development may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; the timing for initiation or completion of, or for availability of data from, clinical trials for UB-311, UB-312, UB-313, VXX-401 or UB-612, and the outcomes of such trials; Vaxxinity’s reliance on collaborative partners and other third parties for development of its product candidates; Vaxxinity’s ability to obtain coverage, pricing or reimbursement for any approved products and acceptance from patients and physicians for any approved indications; delays or other challenges in the recruitment of patients for, or the conduct of, Vaxxinity’s clinical trials; challenges associated with supply and manufacturing activities; and Vaxxinity’s accounting policies. These and other important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of Vaxxinity’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 27, 2023. The forward-looking statements are made as of this date and Vaxxinity does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor ContactMark Joinnidesir@vaxxinity.com Press ContactJon Yumedia@vaxxinity.com

WHITEHALL, Pa., Dec. 6, 2023 /PRNewswire/ -- Researchers at the University of Central Florida College of Medicine (UCF COM) in Orlando, Florida completed research that is very promising in the treatment of Parkinson's disease. They had attended a Parkinson's disease (PD) patient for a non-healing wound who reported a decrease in his hand tremor and freezing of gait when his wound was exposed to a ceramic far-field infrared (cFIR) blanket. The UCF researchers had previously published a study demonstrating that they could increase wound healing using this treatment. Continue Reading Dr. Frederick R. Carrick and Dr. Kiminobu Sugaya Parkinson's disease is the most frequent motor disorder and the second most frequent neurodegenerative disease after Alzheimer's Disease (AD). The tremor, rigidity, and slowness of movement associated with Parkinson's disease affect up to 10 million people throughout the world. Although there are drugs that are used in the treatment of Parkinson's Disease, they provide only temporary relief of the problems of movement and tremors that PD patients suffer from. The lead author of the study, Dr. Frederick R. Carrick, Professor of Neurology at UCF COM, stated that his team used Transgenic Mice that simulate Parkinson's disease in humans. The team found that the Parkinson's mice that were treated with the ceramics had much better control of their balance and movement. Excitingly, even normal healthy mice that were treated with the ceramics improved their balance and movement. Dr. Carrick stated that the most amazing part of their investigation was that the treatment increased the number of brain cells in the areas of the brain associated with Parkinson's disease. They also were able to increase the number of brain cells in normal healthy mice. Dr. Kiminobu Sugaya, Professor of Medicine at UCF COM and Head of the Neuroscience Division at the Burnett School of Biomedical Sciences, is excited about their findings. Dr. Sugaya stated that one of the benefits of using the Gladiator ceramic blanket is that it can be used anywhere without the need for a power supply and without the side effects that are commonly found when injecting chemicals or drugs. He is looking forward to using the cFIR in the treatment of other diseases of the nervous system. The (cFIR) blanket was developed by Gladiator Therapeutics, located in Whitehall, PA. The UCF research team is conducting ongoing research on the use of the Gladiator ceramic blanket in animal models of Alzheimer's disease, Parkinson's disease, traumatic brain injury, and heart failure. They have recently developed a new Alzheimer's therapy combining drugs affecting stem cells that increase the development of brain cells and improve brain function. They are also the first to transplant stem cells isolated from the human brain to aged rats where they showed increased development of new brain cells and improvement of cognition. Besides their research using the cFIR blanket, they are also working on developing a new treatment for glioblastoma multiforme (a type of brain cancer) using gene therapy with a unique delivery system. Please click here to view a copy of the publication of their findings. For more information, visit . About Gladiator Therapeutics Gladiator Therapeutics is an FDA-registered medical device research and manufacturing company utilizing patented non-powered specific far infrared technology. Their corporate office is in Whitehall, PA. The company is dedicated to offering new devices for medical conditions with few treatment options, that can benefit from the cellular regeneration properties of our patented technology.. Contact: Kim Nahf [email protected] SOURCE Gladiator Therapeutics